XML 13 R2.htm IDEA: XBRL DOCUMENT v3.21.1
Condensed Consolidated Balance Sheets - USD ($)
Mar. 31, 2021
Dec. 31, 2020
Current assets:    
Cash and cash equivalents $ 83,634,176 $ 250,728,118
Short-term investments 434,969,528 160,914,935
Accounts receivable 9,911,922 18,559,967
Accounts receivable from affiliated entities 346,974 503,782
Prepaid expenses and other current assets 59,572,236 40,357,456
Prepaid expenses and other current assets from affiliated entities 0 106,432
Total current assets 588,434,836 471,170,690
Fixed assets, net 10,930,312 11,348,144
Investment in affiliated entities 3,629,891 4,460,366
Investment in Geneos 0 434,387
Intangible assets, net 3,010,000 3,146,770
Goodwill 10,513,371 10,513,371
Operating lease right-of-use assets 12,463,006 12,741,296
Other assets 25,881,934 25,957,448
Total assets 654,863,350 539,772,472
Current liabilities:    
Accounts payable and accrued expenses 25,974,530 21,203,808
Accounts payable and accrued expenses due to affiliated entities 768,261 642,969
Accrued clinical trial expenses 7,370,869 9,950,345
Deferred revenue 15,378 46,628
Deferred revenue from affiliated entities 39,000 0
Operating lease liability 2,395,928 2,329,394
Grant funding liability 4,975,484 7,474,310
Grant funding liability from affiliated entities 0 58,500
Total current liabilities 41,539,450 41,705,954
Deferred revenue, net of current portion 75,501 79,214
Operating lease liability, net of current portion 17,438,841 18,063,515
Deferred tax liabilities 32,046 32,046
Grant funding liability from affiliated entity, net of current portion 37,500 37,500
Other liabilities 64,141 57,663
Total liabilities 73,257,201 78,631,714
Stockholders’ equity:    
Preferred stock 0 0
Common stock 209,333 186,851
Additional paid-in capital 1,542,261,467 1,367,406,869
Accumulated deficit (960,598,943) (906,196,812)
Accumulated other comprehensive loss (265,708) (256,150)
Total Inovio Pharmaceuticals, Inc. stockholders’ equity 581,606,149 461,140,758
Total liabilities and stockholders’ equity 654,863,350 539,772,472
6.50% Convertible Senior Notes Due 2024    
Current liabilities:    
Convertible debt 14,069,722 14,139,988
Convertible bonds    
Current liabilities:    
Convertible debt $ 0 $ 4,515,834